RECURSION PHARMACEUTICALS, INC. - Common Stock (RXRX)

CUSIP: 75629V104

Q2 2026 13F Holders as of 30 Jun 2026

Holder snapshot 7 signals
Share change
-3,377,416
Put/Call ratio
25286%
SEC-reported price per share
$3.67
Number of holders
100
Value change
-$12,331,657
Number of buys
46
Open additional details 1 more signal available
Number of sells
33
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
525,448,476

Security key

75629V104

Report period

Q2 2026

Institutions

100

Top holders

10

Ownership snapshot

Top reported holders of RXRX - RECURSION PHARMACEUTICALS, INC. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G 13F 3/4/5 Lead comparable stake: 8.5% 13D/G row: BlackRock, Inc. Showing 1-6 of 15 holder rows.

Quick read

BlackRock, Inc. leads the comparable SEC ownership view at 8.5%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership Top 5
BlackRock, Inc. 8.5%
ARK Investment Management LLC 7.2%
VANGUARD PORTFOLIO MANAGEMENT LLC 6%
STATE STREET CORP 5.5%
VANGUARD CAPITAL MANAGEMENT LLC 5.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BlackRock, Inc.
13D/G 13F
Company
8.5%
$163,467,690
44,541,605 shares
+$24,661,695 30 Jun 2026
ARK Investment Management LLC
13D/G 13F
Company
7.2%
$152,625,941
37,316,856 shares
+$20,329,177 31 Dec 2025
VANGUARD PORTFOLIO MANAGEMENT LLC
13D/G 13F
Vanguard Portfolio Management · Company
6%
$111,674,615
31,369,274 shares
$0 30 Jun 2026
STATE STREET CORP
13F 13D/G
Company · STATE STREET CORPORATION
5.5%
from 13D/G
$87,466,259
28,490,638 shares
31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC
13D/G 13F
Vanguard Capital Management · Company
5.1%
$95,209,099
26,744,129 shares
$0 30 Jun 2026
BAILLIE GIFFORD & CO
13D/G 13F
Company
4.6%
$97,239,635
23,774,972 shares
$0 31 Dec 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
100
Shares
13,457,495
Rows available
100
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders
330
Q2 2026 holders
100
Holder diff
-230
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .